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S U M M A R Y
Objectives: CD4+Foxp3+ regulatory T-cells (Treg) are known to accumulate under certain pathological
conditions. This study was conducted to evaluate the characteristics of and dynamic changes in Treg cells
in chronic hepatitis C (CHC) patients during antiviral therapy.
Methods: One hundred and forty-ﬁve subjects were enrolled in this study, including 105 CHC patients
and 40 healthy donors. The phenotypes and functions of Treg cells were analyzed by ﬂow cytometry.
Results: A signiﬁcant elevation in Treg cells was observed in the peripheral blood of CHC patients
compared with healthy donors. Interestingly, compared with non-suppressive Treg (non-Treg) and
resting Treg (rTreg) cells, activated Treg (aTreg) cells expressed higher levels of ectonucleotidase, CD39,
and CD73. After treatment with interferon alpha (IFN-a) and ribavirin (RBV) in vitro, the frequencies of
total Treg cells and aTreg cells in peripheral blood mononuclear cells (PBMC), as well as the levels of
transforming growth factor beta (TGF-b) secreted by aTreg and non-Treg cells, were signiﬁcantly
decreased. Importantly, it was found that levels of aTreg cells in patients with a sustained virological
response (SVR) were lower than in relapsed patients, suggesting that a high frequency of aTreg cells
might be associated with a poor clinical outcome in HCV infection.
Conclusion: These results demonstrate a decreasing trend in aTreg cells, which express higher levels of
CD39, CD73, and TGF-b, in SVR patients during antiviral therapy.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Hepatitis C virus (HCV) is one of the causes of chronic liver
disease, and HCV infection results in the development of chronic
liver diseases such as cirrhosis and hepatocellular carcinoma.1,2
One of the reasons for the high rates of chronic HCV infection is
immunosuppression, which may be speciﬁcally mediated by the* Corresponding author. Tel.: +86-371-66295320; fax: +86-371-66295625.
** Corresponding author. Tel.: +86-371-67781728.
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1 Zhiqin Li and Yu Ping contributed equally to this article.
http://dx.doi.org/10.1016/j.ijid.2016.02.006
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).regulatory T-cells (Treg cells).3,4 The accumulation of Treg cells
plays a pivotal role in suppressing the antiviral effector T-cells that
are essential for viral clearance.5,6
Recently, a growing body of evidence has indicated that Treg
cells may contribute critically to the induction of immune
tolerance and affect the proliferation, differentiation, and cytokine
secretion of HCV-speciﬁc lymphocytes.7–11 Some research groups
have reported that the depletion of Treg cells increases the
frequency of autoimmune reactions and enhances the develop-
ment of autoimmune disease.12–15 Treg cells show several changes
in number and function during the course of many diseases, such
as those caused by HCV, HIV, and herpes simplex, and autoimmune
diabetes, etc.14–16 Some studies have reported that CD45RA couldciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Characteristics of healthy donors and patients enrolled in this studya
Characteristics Healthy donors
(n = 40, F/M 25/15)
HCV-infected patients
(n = 105, F/M 60/45)
Age, years 46 (40–59) 47 (40–60)
ALT level, IU/ml Negative data 36 (22–50)
AST level, IU/ml Negative data 36 (36–48)
ALP, IU/ml Negative data 59 (55–91)
Albumin level, g/l Negative data 39.7 (35.60–47.20)
Albumin to globulin, g/l Negative data 1.37 (1.18–1.54)
HCV genotype, 1b/2a Negative data 62/43
HCV RNA, log10 IU/ml Negative data 6.10 (5.70–6.16)
HCV, hepatitis C virus; F, female; M, male; ALT, alanine aminotransferase; AST,
aspartate aminotransferase; ALP, alkaline phosphatase.
a Results are presented as the median (range).
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Treg (non-Treg) cells, and activated Treg (aTreg) cells.17,18
CD4+CD45RA+ forkhead box P3 (Foxp3)low Treg cells – antigen-
experienced cells – are named rTreg cells. CD4+CD45RAFoxp3high
Treg cells, named aTreg cells, have strongly suppressive function and
proliferating ability in vivo. CD4+CD45RAFoxp3low Treg cells are
non-Treg cells, which have the function of cytokine secretion.19,20Figure 1. CHC patients had higher amounts of Treg cells, especially aTreg. (A) Study desig
for 48 weeks and 24 weeks, respectively. (B) Representative dot plots of the percentag
chronic HCV-infected patients. (C) The percentages of CD4+Foxp3+ Treg cells and aTreg 
measured by ﬂow cytometry and are presented as percentages. Values are the mean
***p < 0.001. (CHC, chronic hepatitis C; HCV, hepatitis C virus; IFN-a, interferon alpha; RBThe combination therapy of interferon alpha (IFN-a) and
ribavirin (RBV) has shown positive outcomes in more than 80% of
patients with acute HCV infections and in 50% of patients with
chronic HCV infections. To date, it is unclear how Treg cells change in
chronic hepatitis C (CHC) patients during IFN-a and RBV therapy. To
further explore this issue, the present study was performed to
determine whether or not Treg cells take part in the immune
microenvironment of CHC patients during antiviral therapy. The
expression of inhibitory markers and cytokines, such as CD39, CD73,
and transforming growth factor beta (TGF-b), were analyzed in
three subsets of Treg cells. It was found that CD4+Foxp3+ Treg cells
presented a decreasing trend in patients with a sustained virological
response (SVR) during antiviral therapy. Consequently, the data
demonstrated that patients could have a beneﬁcial immune
microenvironment after treatment with IFN-a and RBV.
2. Patients and methods
2.1. Ethics statement
The study was approved by the First Afﬁliated Hospital of
Zhengzhou University. The samples were collected after written
informed consent was obtained. The whole consent procedure wasn: patients infected with genotypes 1b and 2a HCV were treated with IFN-a and RBV
es of Treg cells and three subsets in peripheral CD4+ T-cells in healthy donors and
cells were decreased in patients compared with healthy controls. These data were
 of two independent experiments  stand error of the mean. *p < 0.05, **p < 0.01,
V, ribavirin.).
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Committee of the First Afﬁliated Hospital of Zhengzhou University.
2.2. Patients and samples
One hundred and forty-ﬁve subjects were enrolled in this study
and divided into two groups: CHC patients (n = 105) and healthy
donors (n = 40). The 105 CHC patients were hospitalized during the
period January 2011 to January 2013 in the First Afﬁliated Hospital
of Zhengzhou University and the healthy age-matched control
donors were recruited at the Henan Red Cross Blood Center. The
main clinical and pathological characteristics of the patients are
presented in Table 1.
2.3. Flow cytometry
The cell surface markers were evaluated by six-color ﬂow
cytometry. The acquisition and analysis gates for peripheral blood
mononuclear cells (PBMCs) were determined by characteristic
forward and side-scatter properties of lymphocytes. Data were
acquired using a FACSCanto II ﬂow cytometer (BD Biosciences, San
Jose, CA, USA) and analyzed using Diva software (BD Biosciences,
San Jose, CA, USA). CD4+CD25+ Treg cells were sorted using a
MoﬂoXDP cytometer (Beckman, Brea, CA, USA).
2.4. Surface and intracellular cytokine staining
To determine the frequencies of the three Treg subsets, both cell
surface and intracellular staining were performed. Brieﬂy, mono-
clonal antibodies (mAbs) against surface markers CD3, CD4, CD45RA,
CD39, and CD73 were added to the cell suspension and incubated on
ice for 30 min in the dark. After washing twice, the cells were ﬁxed
and permeabilized with ﬁxation/permeabilization buffer (Biolegend,Figure 2. aTreg cells exhibited higher expression of inhibitory markers and TGF-b in pat
markers CD39, CD73, and TGF-b in HCV patients. (B) Histogram representing the percenta
transforming growth factor beta; HCV, hepatitis C virus.).San Deigo, CA, USA) for 1 h in the dark. Cells were washed twice and
incubated with intracellular mAbs against TGF-b on ice for 20 min in
the dark. After intracellular staining, the cells were washed twice and
examined by six-color ﬂow cytometry. Appropriate isotype antibody
controls were included for each sample.
2.5. The effect of IFN-a and RBV on Treg cells in vitro
PBMCs from patients and healthy donors were isolated by Ficoll
density gradient centrifugation (Tianjin HY, Tianjin, China) and then
washed twice with phosphate buffered saline (PBS). The cells were
resuspended in RPMI1640 (Hyclone, Logan, Utah, USA) containing
10% fetal bovine serum (FBS; Sigma, St. Louis, MO, USA), 100 U/ml
penicillin, and 100 mg/ml streptomycin. RBV (100 mg/ml) and IFN-a
(100 U/ml) were added to the PBMCs. Twelve hours after incubation
in an atmosphere of 5% CO2 at 37 8C, the cells were harvested.
2.6. Statistical analysis
The results are expressed as the mean  standard error of the
mean (SEM) of triplicate determinations. The Student’s t-test was
used to analyze differences between independent data sets with a
normal distribution. Data were plotted using GraphPad Prism version
5.03 and Photoshop version Cs5. A p-value of <0.05 was considered
statistically signiﬁcant.
3. Results
3.1. Clinical response to antiviral treatment
Patient assignment was randomized using simple procedures. A
total of 105 patients chronically infected with HCV were recruited,
of whom 104 completed the treatment (Figure 1). SVR was deﬁnedients infected with HCV. (A) Representative dot plots of the expression of inhibitor
ge expression of CD39, CD73, and TGF-b. *p < 0.05, **p < 0.01, ***p < 0.001. (TGF-b,
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therapy.21 Compared with those infected with genotype 1b HCV
(39/61, 63.93%), a higher percentage of patients with genotype 2a
attained an early virological response (36/43, 83.72%). By
intention-to-treat (ITT) analysis, the rate of SVR was lower in
patients with genotype 1b HCV (37/61, 60.65%) than in patients
with genotype 2a (38/43, 88.37%) (Figure 1A).
3.2. CHC patients had a higher percentage of aTreg cells
The accumulation of CD4+Foxp3+ Treg cells is characteristic of
HCV infection and plays a pivotal role in suppressing effector T-cell
responses that may be essential for viral clearance. The frequencies
of CD4+Foxp3+ Treg cells and the three subsets of Treg cells were
examined in CHC patients and healthy donors. Compared to
healthy donors, patients with chronic HCV infection had a higher
percentage of CD4+Foxp3+ Treg cells (p = 0.042) (Figure 1C). It was
also found that these patients had a higher frequency of aTreg cells
compared to healthy donors, but this was not the case for the rTreg
cells or non-Treg cells (p = 0.037) (Figure 1C). Taken together, these
results indicate that Treg cells, especially aTreg cells, may play an
important role in the pathogenesis of CHC.
3.3. aTreg cells expressed higher levels of inhibitory markers and TGF-
b in patients with chronic HCV infection
As shown in Figure 1, it appears that Treg cells may play an
important role in patients with chronic HCV infection. To evaluate
the suppressive function of Treg cells, the inhibitory markers CD73,
CD39, and TGF-b were detected. CD39, named nucleoside triphos-
phate dephosphorylase, mediates the dephosphorylation of adeno-
sine triphosphate (ATP) to adenosine diphosphate (ADP) and then toFigure 3. Percentages of total Treg cells and aTreg cells were associated with the antiviral 
determined by ﬂow cytometry at the indicated time points. The frequencies of aTreg ce
genotype 1b (B) after in vivo treatment with antiviral therapy. *p < 0.05, **p < 0.01, **50-adenosine monophosphate (AMP); CD73 (ecto-50-nucleotidase)
catalyzes the terminal reaction to convert 50-AMP to adenosine,
which mediates immune suppression.22 Ryzhov et al. found that
TGF-b signaling could directly induce the generation of CD39+CD73+
cells.23 Therefore, the expression of CD39, CD73, and TGF-b was
detected in the three subsets of Treg cells. Higher levels of CD39,
CD73, and TGF-b were found in aTreg cells than in non-Treg and
rTreg cells in patients with HCV infection (Figure 2). Additionally,
there was no difference in the expression of these markers between
patients with genotype 1b and those with genotype 2a (Figure 2B).
The expression of CD39, CD73, and TGF-b on CD8+ T-cells and
CD4+CD25 T-cells from HCV-infected patients and healthy donors
was also examined. Compared with healthy donors, HCV-infected
patients had a higher expression of CD39, CD73, and TGF-b on these
cells (Supplementary Material, Figure S1a, b). These results indicate
that aTreg cells are the major group with inhibitory function in
patients with chronic HCV infection.
3.4. The percentage of aTreg cells decreased in HCV patients during
antiviral therapy
A previous study has reported that Treg cells contribute to HCV
persistence by suppressing HCV-speciﬁc T-cell responses.24 In the
present study it was found that patients with chronic HCV infection
had high levels of Treg and aTreg cells. aTreg cells were found to
express signiﬁcantly higher levels of CD39, CD73, and TGF-b. Thus,
to determine how these cells change in patients with chronic HCV
infection during antiviral therapy, the percentages of Treg subsets
were detected at three time points (Figure 1A). CD4+Foxp3+ Treg
cells showed a dynamically decreasing pattern during antiviral
therapy, not only in patients with genotype 1b, but also in patients
with genotype 2a (p = 0.0013, p = 0.0002) (Figure 3).therapy. Percentages of three Treg subsets in patients with genotypes 2a and 1b were
lls and Treg cells showed a decreasing trend in patients with genotype 2a (A) and
*p < 0.001.
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aTreg cells at 12 weeks of antiviral treatment was much lower than
the percentage at baseline, and there was a more pronounced
decrease at 48 weeks compared with the baseline (p = 0.0045,
p = 0.012) (Figure 3B). The same phenomenon was found in the
patients infected with HCV genotype 2a: the percentage of aTreg
cells was decreased at 12 weeks and had decreased even further at
the 24-week time point (p = 0.038, p = 0.0044) (Figure 3A).
However, there were no changes in non-Treg cells in patients
infected with HCV genotypes 1b and 2a during antiviral therapy
(Figure 3).
It was known that Treg cells would change in patients during
antiviral therapy. To further investigate this issue, PBMCs were
collected from the naive patients who had not undergone any
previous treatment in order to evaluate the effect of IFN-a and RBV
on Treg cells in vitro. The percentage of CD4+Foxp3+ Treg cells was
found to decrease signiﬁcantly in PBMCs at 12 h after treatment
with IFN-a and RBV (p < 0.0001) (Figure 4A). Meanwhile, the
percentages of aTreg, non-Treg, and rTreg cells also showed the
same declining pattern after treatment with IFN-a and RBV
(p = 0.0308, p = 0.0059, p = 0.0013) (Figure 4A). The data showed
that the percentage of aTreg cells in the CD4+ T-cells decreased
signiﬁcantly due to the effect of IFN-a and RBV; aTreg cells may
play an important suppressive role during the course of HCV
chronic infection.Figure 4. TGF-b secreted by aTreg cells decreased after treatment with antiviral drugs in
12 h, PBMCs were analyzed by ﬂow cytometry. (A) Scatter dot plot showing the percent
before and after treatment with IFN-a and RBV. (B) Representative dot plots showing the
HCV. (C) The cytokine TGF-b secreted by three subsets of Treg cells decreased after treat
stand error of the mean. *p < 0.05, **p < 0.01, ***p < 0.001. (TGF-b, transforming growth fa
interferon alpha; RBV, ribavirin.).3.5. The percentage of TGF-b secreted by aTreg cells decreased in HCV
patients in the presence of IFN-a and RBV in vitro
Hall et al. reported that HCV-positive hepatocytes induced
human Treg cells through the production of TGF-b.25 It was
therefore speculated that Treg cells would secrete less TGF-b
after treatment with IFN-a and RBV. To investigate this issue, the
inhibitory cytokines in Treg cell subsets of the PBMCs from CHC
patients were studied after stimulation in vitro. The PBMCs were
divided into two groups: a control group and a group treated
with IFN-a and RBV. It was found that the aTreg population was
the subset that secreted the most TGF-b among the three subsets
of Treg cells (Figure 2B), and the expression of TGF-b in aTreg
cells was reduced after treatment with IFN-a and RBV (p = 0.012)
(Figure 4B, C). Additionally, puriﬁed CD4+CD25+ Treg cells from
HCV-infected patients were obtained and incubated with
antiviral drugs for 12 h. The expression of CD73 on puriﬁed
Treg cells was found to be decreased after treatment with
antiviral drugs. Furthermore, the TGF-b secretion assay showed
the same phenomenon. However, there was no signiﬁcant
change in the expression of CD39 (Supplementary Material,
Figure S2). Taken together, the results indicate that aTreg cells
may play an important role in the immune microenvironment
and that the production of TGF-b decreases during antiviral
therapy. vitro. PBMCs isolated from HCV patients were cultured with IFN-a and RBV. After
ages of CD4+Foxp3+ Treg cells, non-Treg, aTreg, and rTreg in PBMCs of the patients
 suppressed TGF-b expression in three subsets of Treg cells in patients infected with
ment with IFN-a and RBV. Values are the mean of two independent experiments 
ctor beta; PBMCs, peripheral blood mononuclear cells; HCV, hepatitis C virus; IFN-a,
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associated with a poor prognosis
There was a tendency towards decreased percentages of
CD4+Foxp3+ Treg cells and aTreg cells during antiviral therapy.
To prove that the antiviral therapy was effective, the percen-
tages of CD4+Foxp3+ Treg cells and three subsets of Treg cells
were compared between patients with a SVR and those without
a SVR. The percentages of CD4+Foxp3+ Treg cells and aTreg cells
were found to be much lower in patients with a SVR than in
relapsed patients (p = 0.0032, p = 0.0060) (Figure 5). However,
no difference in non-Treg cells or rTreg cells was found between
patients with a SVR and relapsed patients. These results indicate
that aTreg cells may play an important role in CHC patients and
that patients who attain a SVR have a lower frequency of aTreg
cells than those who relapse. Targeting aTreg cells during
antiviral therapy might be a future method to prevent the
relapse of CHC.Figure 5. The higher percentages of CD4+Foxp3+ Treg and aTreg were associated with a p
without a SVR. Frequencies of CD4+Foxp3+ Treg (A), non-Treg (B), rTreg (C), and aTreg (D
***p < 0.001. (HCV, hepatitis C virus; PBMCs, peripheral blood mononuclear cells; SVR,4. Discussion
HCV infection is a global health problem and is associated with
ineffective virus-speciﬁc CD4+ and CD8+ T-cells responses.26,27
IFN-a and RBV combination therapy has been a popular treatment
for CHC patients. IFN-a induces antiviral responses via interactions
with speciﬁc cell surface receptors,28–31 activating natural killer
(NK) cells and CD8+ T-cells and enhancing their cytotoxic
potential.32 RBV, a nucleoside analogue, can signiﬁcantly enhance
the effects of IFN-a on suppression of HCV replication by inducing
interferon-stimulated genes.33 In 2011, the ﬁrst direct-acting
antiviral drugs, telaprevir and boceprevir, were approved by
United States Food and Drug Administration. Soon afterwards,
three new direct-acting antiviral drugs, sofosbuvir, simeprevir, and
daclatasvir, were approved and launched in a number of Western
countries.34,35 However, these drugs are not widely used in
developing countries, such as China and India, due to their
exorbitant price. Therefore, the combination of IFN-a and RBVoor prognosis in HCV infection. PBMCs were collected from patients with a SVR and
) cells were detected in patients with a SVR and without a SVR. *p < 0.05, **p < 0.01,
 sustained virological response.).
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This study was performed to research the underlying mechanism of
the immune microenvironment in patients with CHC treated with
IFN-a and RBV. In this study, it was found that patients with CHC had
higher levels of Treg cells than healthy donors. Treg cells can
suppress the cytokine production and proliferation of virus-speciﬁc
T effector cells.36–40 Therefore, the immunosuppression of Treg cells
in patients with CHC during antiviral therapy was mainly studied.
Consistent with a previous study, it was observed that Treg cells
were increased in the PBMCs of patients infected with HCV.41
Furthermore, the change in three subsets of Treg cells was
determined and it was found that aTreg cells represented the group
playing a major role in the pathological mechanism in patients
infected with HCV. In order to investigate the characteristics of the
Treg subsets in these patients, some inhibitory markers expressed on
these three subsets of Treg cells were studied. aTreg cells that express
high levels of CD39 and CD73 are critical for the immunosuppressive
activity of Treg cells.42 CD39 hydrolyzes extracellular ATP and ADP
into AMP, and CD73 catalyzes the dephosphorylation of AMP to
adenosine. Regateiro et al. reported that active CD39 and CD73
protect Treg cells from apoptosis.22Surprisingly, in the present study,
higher levels of CD39 and CD73 were found on aTreg cells, which had
highly suppressive functions and proliferating abilities in vivo,
compared to those on non-Treg and rTreg cells in patients with
chronic HCV infection (genotypes 1b and 2a) during the course of
antiviral treatment. Furthermore, it was observed that Treg cells also
secreted TGF-b, the signaling of which has been conﬁrmed as an
important mechanism for Treg cell-mediated suppression.19,43
Another important ﬁnding of the present study was the
signiﬁcant difference in aTreg cells but not in non-Treg cells or
rTreg cells in patients with a SVR compared to those without a SVR.
The data suggest that the increase in Treg cells might lead to the
exhaustion of T-cells in CHC patients, and patients without a SVR
might have a worse immune microenvironment during antiviral
therapy. Therefore, the frequencies of Treg cell subsets might serve
as a predictor of the response to antiviral therapy. The balance of
Treg cells during antiviral therapy might be critical in the control of
immune protection and immune pathology during viral infection.
In conclusion, the results of the present study suggest that
aTreg cells may play an important role in patients with chronic
HCV infection during antiviral therapy. It was shown in this study
that aTreg cells express high levels of CD39, CD73, and TGF-b. In
addition, aTreg cells present a decreasing trend during antiviral
therapy, and patients with a SVR have a lower frequency of aTreg
cells than those who relapse.
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